AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05129644
Drug: P1101 (270 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
Trial: NCT00100971
Drug: autologous tumor cell vaccine
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00100971
Drug: therapeutic autologous dendritic cells
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03606902
Drug: Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
Trial: NCT04516447
Drug: ZN-c3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug
Trial: NCT04516447
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) is an approved drug
Trial: NCT02718404
Drug: MR contrast media and medications
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
Trial: NCT02976909
Drug: Paclitaxel+Cisplatin+5fluorouracil
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
Trial: NCT00759941
Drug: Placebo eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop three times a day in both eyes for 3 months
Trial: NCT01723384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01054443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00671736
Drug: Moli1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,5 ml inhalation solution, 8 weeks treatment period
Trial: NCT00671736
Drug: Moli1901 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,5 ml placebo solution, 8 weeks treatment period
Trial: NCT03827096
Drug: Suspension of human autologous MSC 3P in 1.5 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
Trial: NCT00984386
Drug: Zesteem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
Trial: NCT00873483
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles
Trial: NCT00984386
Drug: Zesteem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
Trial: NCT00984386
Drug: Zesteem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
Trial: NCT00984386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal placebo, 100μl administered once before punch biopsy
Trial: NCT02140268
Drug: AZD1722
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
Trial: NCT00288431
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered at 60 mg/m2 intravenously every 3 weeks
Trial: NCT01061073
Drug: spasfon
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03783312
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
Trial: NCT03783312
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
Trial: NCT04215731
Drug: Induction chemotherpay with FOLFOX
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles
Trial: NCT04062097
Drug: Vitamin K antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This drug group includes the active substances phenprocoumon and warfarin.
Trial: NCT03012503
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
Trial: NCT00905164
Drug: Topamax® Capsules, 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topamax® Capsules, 2 x 25 mg
Trial: NCT01173666
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
Trial: NCT04396756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00091949
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an inactive substance
Trial: NCT00269217
Drug: niacin (+) laropiprant (+) simvastatin
RxNorm normalized name: niacin / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment 12 Weeks
Trial: NCT00269217
Drug: Comparator: simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment 12 Weeks
Trial: NCT01632696
Drug: I-124 PGN650 for PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
Trial: NCT01105481
Drug: Placebo add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
Trial: NCT03347721
Drug: Lubricant Gel
RxNorm normalized name: Surgilube Lubricant Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubricating gel
Trial: NCT02083900
Drug: Hydrocolloid Dressing (DuoDERM CGF)
RxNorm normalized name: psyllium hydrocolloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
Trial: NCT03780673
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day for 12 months
Trial: NCT03666663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Saline using the Sphenocath device- cleared by FDA
Trial: NCT01841099
Drug: Placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided by Ferring Pharma
Trial: NCT01704716
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
Trial: NCT01704716
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is given during Induction Treatment (R3 arm modified N7)
Trial: NCT01004822
Drug: CVX-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Trial: NCT01004822
Drug: CVX-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Trial: NCT01004822
Drug: CVX-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Trial: NCT02231086
Drug: Standard adjuvant systemic chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
Trial: NCT01004822
Drug: CVX-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Trial: NCT01004822
Drug: CVX-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Trial: NCT01004822
Drug: CVX-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Trial: NCT01004822
Drug: CVX-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Trial: NCT01004822
Drug: CVX-241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Trial: NCT00547404
Drug: P276-00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
Trial: NCT00551811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be intended to be administered orally.
Trial: NCT00223158
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01710501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match grazoprevir tablets to maintain dose blinding
Trial: NCT00628667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03081117
Drug: Insulin, intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin administered by specialized, non-commercial intranasal drug delivery device
Trial: NCT03081117
Drug: Placebo, intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution administered by specialized, non-commercial intranasal drug delivery device
Trial: NCT04003467
Drug: Placebo of EBP05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT01696110
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin monotherapy
Trial: NCT04057326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets/time, 3 times daily,Oral Administration.
Trial: NCT02201394
Drug: Aspirin maintenance dose
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg once daily x 7 days
Trial: NCT00632814
Drug: rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
Trial: NCT00632814
Drug: rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection twice per week (30 IU/kg \[day 1\] + 40 IU/kg \[day 4\]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
Trial: NCT00632814
Drug: rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg \[day 1, 3, 5\]) for 9 months. No escalation opportunity for patients in this group
Trial: NCT01334502
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT01334502
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT03980080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle study drug
Trial: NCT01674010
Drug: ELND005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03159455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration - 28 days
Trial: NCT01697670
Drug: Photodynamic therapy with Gliolan
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
Trial: NCT00904605
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
Trial: NCT02426164
Drug: bupivacaine HCl, morphine, epinephrine, methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
Trial: NCT03027609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo (+ SOC antibiotics)
Trial: NCT01197118
Drug: chemotherapy alone following radical resection
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1\~5, i.v.; leucovorin, 200 mg/m2/day on day 1\~5, i.v.; every 21 days repeated, for 6 cycles.
Trial: NCT00918255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection using prefilled syringe containing 0.8 milliliters
Trial: NCT00813241
Drug: celecoxib reference formulation
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg single oral dose of celecoxib tablets
Trial: NCT00813241
Drug: celecoxib test formulation A1
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg single oral dose of celecoxib A1 formulation tablets
Trial: NCT00813241
Drug: celecoxib test formulation B2
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg single oral dose of celecoxib B2 formulation tablets
Trial: NCT00813241
Drug: celecoxib test formulation C1
RxNorm normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg single oral dose of celecoxib Cl formulation tablets
Trial: NCT00408317
Drug: Ultrase® MT20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
Trial: NCT00408317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
Trial: NCT02909400
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04098991
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
Trial: NCT04237597
Drug: CSG452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSG452 tablets
Trial: NCT03169127
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
Trial: NCT02641691
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02641691
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00403429
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03057769
Drug: Papillary epinephrine spraying
RxNorm normalized name: epinephrine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
Trial: NCT03057769
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
Trial: NCT01469416
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20 mg PO x 1
Trial: NCT01605708
Drug: REGN846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1
Trial: NCT00960882
Drug: DMMET-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1050.6 mg daily for 30 days
Trial: NCT01484587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
Trial: NCT00811499
Drug: ARRY-371797, p38 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule
Trial: NCT00811499
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01374438
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules given once daily for 90 days
Trial: NCT03938259
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
Trial: NCT00836693
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet administered orally once a day for 12 weeks.
Trial: NCT00006461
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02741063
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo (24 IU)
Trial: NCT00811499
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule